- Home
- EQR vs MRNA Comparison
EQR vs MRNA Comparison
Compare EQR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | MRNA |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5B | 26.7B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EQR | MRNA |
|---|---|---|
| Price | $67.93 | $54.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 12 |
| Target Price | ★ $69.63 | $34.27 |
| AVG Volume (30 Days) | 2.4M | ★ 6.9M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | 8.09 | ★ 21.77 |
| EPS | ★ 0.24 | N/A |
| Revenue | $2,701,075,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $4.07 | $9.36 |
| Revenue Next Year | $3.14 | $15.43 |
| P/E Ratio | $284.50 | ★ N/A |
| Revenue Growth | ★ 4.76 | 4.29 |
| 52 Week Low | $57.57 | $22.28 |
| 52 Week High | $71.50 | $85.60 |
Technical Indicators
Market Signals| Indicator | EQR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 37.02 |
| Support Level | $58.62 | $45.69 |
| Resistance Level | $69.03 | $54.50 |
| Average True Range (ATR) | 1.24 | 3.73 |
| MACD | -0.22 | -2.47 |
| Stochastic Oscillator | 11.57 | 1.27 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 85,000 units and is developing two additional properties with 665 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.